| Title |
Epstein–Barr Virus Infection and Multiple Sclerosis: A Review
|
|---|---|
| Published in |
Journal of Neuroimmune Pharmacology, April 2010
|
| DOI | 10.1007/s11481-010-9201-3 |
| Pubmed ID | |
| Authors |
Alberto Ascherio, Kassandra L. Munger |
| Abstract |
Epstein-Barr virus (EBV) infection results in a life-long persistence of the virus in the host's B-lymphocytes and has been associated with numerous cancers including Burkitt's lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma. There is considerable evidence that EBV infection is a strong risk factor for the development of multiple sclerosis. Early age at primary EBV infection is typically asymptomatic, but primary infection during adolescence or adulthood often manifests as infectious mononucleosis, which has been associated with a two- to threefold increased risk of MS. Most importantly, MS risk is extremely low in individuals who are EBV negative, but it increases several folds following EBV infection. Additional evidence supporting a role for EBV in MS pathogenesis includes the observations of elevated antibodies to EBV antigens (especially EBV nuclear antigen-1) prior to the onset of MS, and an increased risk of MS among EBV-positive children. The biological mechanism by which EBV may cause MS is not known, but several possibilities are discussed. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 45% |
| Germany | 1 | 9% |
| Gibraltar | 1 | 9% |
| Unknown | 4 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 91% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 271 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| United Kingdom | 2 | <1% |
| Spain | 2 | <1% |
| Czechia | 1 | <1% |
| Hungary | 1 | <1% |
| Portugal | 1 | <1% |
| Unknown | 261 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 43 | 16% |
| Student > Ph. D. Student | 42 | 15% |
| Researcher | 34 | 13% |
| Student > Bachelor | 25 | 9% |
| Unspecified | 19 | 7% |
| Other | 50 | 18% |
| Unknown | 58 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 67 | 25% |
| Agricultural and Biological Sciences | 35 | 13% |
| Neuroscience | 22 | 8% |
| Biochemistry, Genetics and Molecular Biology | 21 | 8% |
| Unspecified | 19 | 7% |
| Other | 42 | 15% |
| Unknown | 65 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2023.
All research outputs
#1,384,336
of 25,331,507 outputs
Outputs from Journal of Neuroimmune Pharmacology
#37
of 601 outputs
Outputs of similar age
#4,507
of 101,292 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#1
of 9 outputs
Altmetric has tracked 25,331,507 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 601 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them